Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rolofylline

Drug Profile

Rolofylline

Alternative Names: KF-15372; KW-3902; KW-3902 Injectable Emulsion; KW-3902IV; MK-7418

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Hakko; Merck & Co
  • Class Neuroprotectants; Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute heart failure; Cognition disorders; Hypertension

Most Recent Events

  • 02 Sep 2009 Final safety and efficacy data from the PROTECT-1 and PROTECT-2 trials in Acute heart failure presented at the Annual Congress of the European Society of Cardiology (ESC-2009)
  • 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in Canada (IV)
  • 30 Jun 2009 Discontinued - Phase-III for Acute heart failure in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top